Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Targeted Anticancer Therapies Congress 2023

Novel kinase inhibitors

BRAF inhibitors: Targeting class II/III alterations

Date

07 Mar 2023

Session

Novel kinase inhibitors

Topics

Clinical Research;  Translational Research;  Targeted Therapy;  Molecular Oncology;  Genetic and Genomic Testing

Tumour Site

Presenters

Alison Schram

Authors

A. Schram

Author affiliations

  • Medicine Department, MSKCC - Memorial Sloan Kettering Cancer Center, 10065 - New York/US

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Q&A

Presenter: Alison Schram

Session: Novel kinase inhibitors

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.